Orencia Abatacept Drug Market Report 2026

Orencia Abatacept Drug Market Overview

• Orencia Abatacept Drug market size has reached to $3.92 billion in 2025 • Expected to grow to $5.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Rising Incidence Of Autoimmune Disorders Fuels Demand For Biologic Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Orencia Abatacept Drug Market?

Orencia abatacept drug is a biologic drug prescribed for autoimmune disorders that functions by blocking the activation of T-cells. This medication belongs to the class of selective co-stimulation modulators, thereby reducing immune system overactivity helping to lower inflammation and safeguard joints from damage. The main product types in the orencia abatacept drug market are subcutaneous injection and intravenous infusion. A subcutaneous injection entails delivering medication into the tissue just beneath the skin using a needle. These are used for various applications such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and others. It is distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.

What Is The Orencia Abatacept Drug Market Growth Forecast?

The orencia abatacept drug market size is expected to see strong growth in the next few years. It will grow to $5.28 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growth in biologic immunotherapy demand, expansion of home-based biologic administration, rising autoimmune disease burden, increased patient preference for targeted therapies, continued innovation in immune modulation. Major trends in the forecast period include increasing use of targeted immunomodulatory therapies, rising adoption in rheumatoid and psoriatic arthritis, growth of biologic disease-modifying treatments, expansion of subcutaneous self-administration, increased focus on long-term autoimmune disease control.

Global Orencia Abatacept Drug Market Segmentation

1) By Product Type: Subcutaneous Injection, Intravenous Infusion 2) By Application: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels Subsegments: 1) By Subcutaneous Injection: Prefilled Syringes, Auto-Injector Pens 2) By Intravenous Infusion: Hospital-Administered Infusion, Outpatient Infusion Center Administration

What Are The Drivers Of The Orencia Abatacept Drug Market?

The increasing prevalence of autoimmune diseases is expected to propel the growth of the orencia abatacept drug market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy cells and tissues. The increasing autoimmune diseases are due to genetic, environmental, and lifestyle factors. Orencia (abatacept) drug supports autoimmune disease patients by selectively modulating T-cell activation, reducing inflammation, and preventing joint damage, thus helping to control disease progression, improve quality of life, and minimize the need for other immunosuppressive treatments in conditions such as rheumatoid arthritis and psoriatic arthritis. For instance, in February 2025, according to the Australian Broadcasting Corporation, an Australia-based national public broadcaster, inflammatory bowel disease currently impacts almost 180,000 Australians, with Crohn's Disease affecting 93,700 and Ulcerative Colitis affecting 80,430 individuals, and the total number is expected to rise to 200,000 in the next 10 years. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the orencia abatacept drug industry. Rising personalized medicine is expected to propel the growth of the orencia abatacept drug market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare strategies to the individual characteristics of each patient, such as their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The rising personalized medicine is due to advancements in genomic technologies, increased understanding of molecular biology, growing availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while minimizing side effects. Orencia (abatacept) drug contributes to personalized medicine by offering targeted immunotherapy that specifically modulates the activation of T-cells, allowing healthcare providers to tailor treatment plans based on individual patient profiles, disease severity, and response to therapy, ensuring more effective and customized care for those with autoimmune disorders. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, rising personalized medicine drives the orencia abatacept drug industry.

Key Players In The Global Orencia Abatacept Drug Market

Major companies operating in the orencia abatacept drug market are Bristol-Myers Squibb Company

What Are Latest Mergers And Acquisitions In The Orencia Abatacept Drug Market?

In January 2023, Lotte Biologics Co. Ltd., a South Korea-based biotechnology company, acquired biopharmaceutical production facility in New York from Bristol Myers Squibb Company for $160 million. With this acquisition, Lotte Biologics aims to expand its manufacturing capabilities and strengthen its CDMO services. Bristol Myers Squibb Company is a US-based pharmaceutical company specializes in developing biopharmaceutical products including orencia abatacept drug.

Regional Insights

North America was the largest region in the orencia abatacept drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Orencia Abatacept Drug Market?

The orencia abatacept drug consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Orencia Abatacept Drug Market Report 2026?

The orencia abatacept drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the orencia abatacept drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.